Results filtered:Study status:
Closed for Enrollment
Closed for Enrollment
A Biobank for Pancreatic Diseases
To develop a resource (bank) of biospecimens and data collected from individuals with pancreatic diseases to facilitate discovery and development of novel biomarkers of risk and early detection, severity prediction, etiology and response to therapy.
Automating Colonoscopy Follow-up to Facilitate Appropriate Colonoscopy Surveillance
The primary goals of this project will be to standardize and enhance recommendations for colonoscopy surveillance intervals across the divisions of GIH and CRS and throughout the clinic practice
Mayo Center for Cell Signaling Biobank (C-SiG Biobank)
The purpose of this study is to facilitate discovery and development of novel biomarkers of risk and early detection, etiologic factors relating to liver disease, and novel targeted therapeutic and chemopreventive strategies for liver disease such as PSC, PBC, PLD, NAFLD, NASH, ASH, HCC, donors (non-diseased and diseased) for liver transplant or non-liver diseased subjects scheduled for surgery will serve as controls.
Mayo Clinic Cancer Genomics Service Line Biorepository
Eau Claire, Wis.,
The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies.
Prospective Study to Evaluate the Association of Pre-treatment Neutrophil to Lymphocyte ratio with Intestinal Permeability in Stage 3 Colon Cancer Patients Receiving Chemotherapy
To study intestinal permeability in participants with stage 3 colon cancer before and during chemotherapy and compare with controls with normal colon, chronic ulcerative colitis (CUC) and carcinoid syndrome
To study the correlation between intestinal permeability and symptoms severity during 5-FU chemotherapy
To study the correlation between intestinal permeability and neutrophils to lymphocytes ratio (NLR) before and during chemotherapy
To analyze the changes in expression levels of genes encoding intercellular junction proteins in all groups
To determine if diarrhea in participants with carcinoid syndrome is associated with increasedintestinal permeability
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer overtime. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.